Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Slow-release dexamethasone does not improve success rate of vitrectomy

06 Mar 2017

Adjunctive slow-release dexamethasone implant (Ozurdex) does not improve the outcomes in eyes undergoing vitreoretinal surgery with silicone oil for proliferative vitreoretinopathy (PVR), according to a recent study.

To test the efficacy of Ozurdex, researchers randomized 140 patients requiring vitrectomy surgery with silicone oil for retinal detachment with established PVR (Grade C) to either standard care (control) or study treatment (adjunct; injection of 0.7 mg of slow-release dexamethasone) in a 1:1 allocation ratio.

Of the patients, 138 had primary outcome data (proportion of patients with a stable retinal reattachment with removal of silicone oil without additional vitreoretinal surgical intervention at 6 months.

Anatomic success was similar between the two treatment groups (49.3 vs 46 percent for adjunct and control, respectively; odds ratio, 0.89; 95 percent CI, 0.46 to 1.74; p=0.733).

At 6 months, the mean visual acuity was 38.3 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the adjunct group and 40.2 ETDRS letters in the control group. Both groups also showed similar secondary anatomic outcomes (complete/posterior reattachment rates and PVR recurrence).

There were also fewer adjunct patients who had cystoid macular oedema (42.7 percent) or a foveal thickness of >300 μm (47.6 percent) compared with controls (67.2 and 67.7 percent, respectively; p=0.004 and p=0.023) at 6 months.

“Further clinical trials are indicated to improve anatomic and visual outcomes in these eyes, but this study suggests that there is a greater reduction in CMO observed at 6 months in vitrectomized eyes treated with slow-release dexamethasone,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Sep 2016
Digoxin, as a new or preexisting therapy, does not increase mortality following acute phase of ST-elevation myocardial infarction (STEMI), as shown in the MAGIC study.
15 Apr 2016
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.
22 Mar 2017
Patients often seek consultation at the pharmacy for superficial skin infection. The goal of this activity is to improve pharmacists' knowledge on strategies to manage bacterial skin infection.
 
Please click here to access this module
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.